PSMA-targeted radioligand therapy outcomes vary by patient characteristics and disease burden in metastatic castration-resistant prostate cancer
Prior chemo and liver spread worsen outcomes for prostate cancer patients on PSMA therapy
A systematic review and meta-analysis of 4,819 patients with metastatic castration-resistant prostate cancer reveals that prior chemotherapy…
A large review of 4,819 patients found that prior chemotherapy and liver spread worsen survival. This helps doctors predict who benefits mos…
